NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia, BCR-ABL1 Positive

Interventions: Drug: Imatinib Mesylate
Drug: Dasatinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2003-10-07

Last Posted Date: 2025-05-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 406

Registration Number: NCT00070499

Locations: 🇺🇸
Eureka Hospital, Eureka, Illinois, United States
🇺🇸
Galesburg Cottage Hospital, Galesburg, Illinois, United States
🇺🇸
Valley Radiation Oncology, Peru, Illinois, United States

and more 338 locations

Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma

Phase 2

Completed

Conditions: Childhood High-grade Cerebral Astrocytoma
Childhood Oligodendroglioma
Recurrent Childhood Brain Stem Glioma
Recurrent Childhood Cerebellar Astrocytoma
Recurrent Childhood Cerebral Astrocytoma
Recurrent Childhood Medulloblastoma
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Recurrent Childhood Visual Pathway and Hypothalamic Glioma

Interventions: Drug: tipifarnib

First Posted Date: 2003-10-07

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT00070525

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Phase 1

Completed

Conditions: Male Breast Carcinoma
Stage IIIA Breast Cancer
Adult Solid Neoplasm
Inflammatory Breast Carcinoma
Stage IIIB Breast Cancer

Interventions: Drug: Capecitabine
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Tipifarnib

First Posted Date: 2003-10-07

Last Posted Date: 2015-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT00070252

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of Wisconsin Medical School, Milwaukee, Wisconsin, United States

and more 4 locations

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

Phase 3

Terminated

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage III Colon Cancer
Stage III Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: oxaliplatin
Drug: leucovorin calcium
Drug: capecitabine
Biological: bevacizumab
Drug: fluorouracil
Other: laboratory biomarker analysis

First Posted Date: 2003-10-07

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2200

Registration Number: NCT00070122

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer

Phase 2

Terminated

Conditions: Liver Metastases
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: oxaliplatin
Drug: capecitabine
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2003-10-07

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00070265

Locations: 🇺🇸
University of Texas, Houston, Texas, United States

Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer

Phase 1

Completed

Conditions: Stage II Breast Cancer
Stage I Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions: Procedure: therapeutic conventional surgery
Drug: celecoxib
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-10-07

Last Posted Date: 2016-12-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00070057

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Phase 2

Terminated

Conditions: Recurrent Bladder Cancer
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Urethral Cancer
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Distal Urethral Cancer
Proximal Urethral Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder
Urethral Cancer Associated With Invasive Bladder Cancer

Interventions: Biological: trastuzumab

First Posted Date: 2003-09-30

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00004856

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer

Phase 2

Completed

Conditions: Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer

Interventions: Drug: bromodeoxyuridine
Procedure: conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2003-09-30

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00003832

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States

Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2

Phase 2

Completed

Conditions: Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Biological: trastuzumab
Other: laboratory biomarker analysis

First Posted Date: 2003-09-30

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 84

Registration Number: NCT00004883

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

ORWH:SCOR on Sex and Gender Factors Affecting Women's Incontinence

Completed

Conditions: Urinary Incontinence
Diabetes

First Posted Date: 2003-09-26

Last Posted Date: 2025-05-04

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 2161

Registration Number: NCT00069368

Locations: 🇺🇸
Kaiser Permanente, Northern California, Division of Research, Oakland, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy